ACPU
BMRN icon

Arrowgrass Capital Partners (US)’s BioMarin Pharmaceuticals BMRN Stock Holding History

Arrowgrass Capital Partners (US)’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-196,478
Closed -$16.8M – 204
2019
Q2 		$16.8M Sell
196,478
-61,900
-24% -$5.3M 0.4% 72
2019
Q1 		$23M Sell
258,378
-90,600
-26% -$8.4M 0.68% 36
2018
Q4 		$29.7M Buy
348,978
+16,443
+5% +$1.56M 1.1% 12
2018
Q3 		$32.2M Sell
332,535
-11,206
-3% -$1.12M 0.99% 21
2018
Q2 		$32.4M Buy
343,741
+97,733
+40% +$8.56M 1.11% 23
2018
Q1 		$19.9M Buy
246,008
+9,166
+4% +$787K 0.68% 38
2017
Q4 		$21.1M Buy
236,842
+5,334
+2% +$464K 0.2% 119
2017
Q3 		$21.5M Buy
231,508
+42,139
+22% +$3.72M 0.16% 157
2017
Q2 		$17.2M Buy
189,369
+15,015
+9% +$1.37M 0.13% 206
2017
Q1 		$15.3M Sell
174,354
-3,991
-2% -$355K 0.16% 184
2016
Q4 		$14.8M Buy
178,345
+123,653
+226% +$10.6M 0.17% 125
2016
Q3 		$5.06M Buy
54,692
+5,742
+12% +$541K 0.07% 211
2016
Q2 		$3.81M Buy
+48,950
New +$4.16M 0.04% 218
2015
Q1 		– Sell
-281,676
Closed -$29.8M – 420
2014
Q4 		$25.5M Buy
281,676
+84,102
+43% +$6.99M 0.45% 33
2014
Q3 		$14.3M Buy
197,574
+48,353
+32% +$3.18M 0.35% 49
2014
Q2 		$9.28M Buy
149,221
+68,914
+86% +$4.16M 0.27% 71
2014
Q1 		$5.48M Buy
+80,307
New +$5.92M 0.22% 95
2013
Q4 		– Sell
-475,980
Closed -$34.4M – 158
2013
Q3 		$34.4M Buy
+475,980
New +$31.6M 1.29% 15

Other funds holding BMRN

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Arrowgrass Capital Partners (US)'s BMRN Position: Q3 2019 in Review

Arrowgrass Capital Partners (US) sold out of BioMarin Pharmaceuticals (BMRN) in Q3 2019, closing a stake of 196,478 shares — an estimated $16.8M sold.

Arrowgrass Capital Partners (US) first reported a position in BMRN in Q3 2013 and held it in 18 quarters. The position peaked at $34.4M in Q3 2013. 436 funds tracked by Wall St. Rank hold BMRN as of Q3 2019.

  • Arrowgrass Capital Partners (US) reported no remaining BioMarin Pharmaceuticals position as of Q3 2019 after selling out during the quarter.
  • Arrowgrass Capital Partners (US) sold 196,478 BioMarin Pharmaceuticals shares in Q3 2019, an estimated $16.8M.
  • Arrowgrass Capital Partners (US) first reported a position in BioMarin Pharmaceuticals in Q3 2013 and held it in 18 quarters.
  • Arrowgrass Capital Partners (US)'s BioMarin Pharmaceuticals position peaked at $34.4M in Q3 2013.
  • 436 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2019.

Based on Arrowgrass Capital Partners (US)'s 13F filing for Q3 2019, filed 14 Nov 2019.